LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Subscribe To Our Newsletter & Stay Updated
